Chembio Diagnostics Appoints Christine Rousseau, Ph.D. as Vice President, Corporate Development
July 19 2018 - 8:00AM
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care
("POC") diagnostic testing, today announced the appointment of
Christine M. Rousseau, Ph.D. as Vice President, Corporate
Development, effective immediately. In this newly created position,
Dr. Rousseau will focus on the Company’s POC infectious disease
diagnostics strategy and execution, including HIV Self-Testing and
Fever & Tropical Diseases, as well as technology collaborations
that leverage the Company’s patented DPP® technology platform and
scientific expertise.
Prior to joining Chembio, Dr. Rousseau spent
nine years at the Bill & Melinda Gates Foundation, most
recently serving as Senior Program Officer, Global Health,
Integrated Technology Solutions. While there, she directed over
$250 million in assets for the development, commercialization, and
scale-up of immune, molecular and cellular diagnostic technologies,
including a significant role in HIV Self-Testing. Previously, Dr.
Rousseau spent ten years as a research scientist and faculty member
at the University of Washington, with emphasis in the areas of HIV
and HCV. Earlier in her career, she was a Senior Fellow at the Fred
Hutchinson Cancer Research Center and HIV Director & Founding
Board Member of the Sustainable Sciences Institute.
“We believe our point-of-care products,
including our patented DPP® technology platform, have enormous
potential in the infectious disease market and other markets that
we are pursuing through collaborations,” stated John Sperzel,
Chembio’s Chief Executive Officer. “Christine’s deep, global
experience in the field of point-of-care testing for infectious
diseases, coupled with her outstanding reputation and industry-wide
relationships, make her an ideal candidate for this important new
role.”
“I am excited to join Chembio’s leadership team
at this key point in the Company’s history,” said Dr. Rousseau. “I
look forward to contributing to the corporate strategy and its
implementation, building on the significant accomplishments Chembio
has already achieved.”
Dr. Rousseau received a Ph.D. in Molecular and
Cell Biology from University of California Berkeley, a M.S. in
Epidemiology from the University of Washington, and a B.S. in
Molecular Genetics from Ohio State University.
About Chembio
DiagnosticsChembio is a leading point-of-care diagnostics
company focused on detecting and diagnosing infectious diseases.
The company’s patented DPP® technology platform, which uses a small
drop of blood from the fingertip, provides high-quality,
cost-effective results in 15-20 minutes. Coupled with Chembio’s
extensive scientific expertise, its novel DPP® technology offers
broad market applications beyond infectious disease, a number of
which are under active development with collaboration partners.
Chembio’s products are sold globally, directly and through
distributors, to hospitals and clinics, physician offices, clinical
laboratories, public health organizations, government agencies, and
consumers. Learn more at www.chembio.com.
Forward-Looking
StatementsStatements contained herein that are not
historical facts may be forward-looking statements within the
meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or
current expectations of the Company and its management. Such
statements, which are estimates only, reflect management's current
views, are based on certain assumptions, and involve risks and
uncertainties. Actual results, events, or performance may differ
materially from the above forward-looking statements due to a
number of important factors, and will be dependent upon a variety
of factors, including, but not limited to, Chembio's ability to
obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products.
Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that
occur after the date hereof or to reflect any change in Chembio's
expectations with regard to these forward-looking statements or the
occurrence of unanticipated events. Factors that may impact
Chembio's success are more fully disclosed in Chembio's most recent
public filings with the U.S. Securities and Exchange
Commission.
Media contacts:
Chembio DiagnosticsLynn Pieper LewisGilmartin
Group(415) 937-5402investor@chembio.com |
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Apr 2023 to Apr 2024